Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model.

Literature DB >> 25682284

The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model.

Yunze Xu¹, Qi Zhu, Dongning Chen, Zhoujun Shen, Weiqing Wang, Guang Ning, Yu Zhu.

Abstract

This study aims to investigate the effect of heat shock protein 90 (HSP90) inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) in the malignant pheochromocytoma using a xenograft mouse model. Treatment with 17-AAG induced a marked reduction in the volume and weight of PC12 pheochromocytoma cell tumor xenografts in mice. Furthermore, 17-AAG also significantly inhibited the expression of HSP90 and its client proteins. Our results validated HSP90 as an important target in pheochromocytoma and provided rationale for the testing of HSP90 inhibitors as a promising therapeutic agent in the antitumor therapy of pheochromocytoma.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2015 PMID： 25682284 DOI： 10.1007/s13277-015-3162-3

Source DB: PubMed Journal: Tumour Biol ISSN： 1010-4283

16 in total

1. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.

Authors: Kamalika Moulick; James H Ahn; Hongliang Zong; Anna Rodina; Leandro Cerchietti; Erica M Gomes DaGama; Eloisi Caldas-Lopes; Kristin Beebe; Fabiana Perna; Katerina Hatzi; Ly P Vu; Xinyang Zhao; Danuta Zatorska; Tony Taldone; Peter Smith-Jones; Mary Alpaugh; Steven S Gross; Nagavarakishore Pillarsetty; Thomas Ku; Jason S Lewis; Steven M Larson; Ross Levine; Hediye Erdjument-Bromage; Monica L Guzman; Stephen D Nimer; Ari Melnick; Len Neckers; Gabriela Chiosis
Journal: Nat Chem Biol Date: 2011-09-25 Impact factor: 15.040

2. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.

Authors: Simon Pacey; Martin Gore; David Chao; Udai Banerji; James Larkin; Sarah Sarker; Karen Owen; Yasmin Asad; Florence Raynaud; Mike Walton; Ian Judson; Paul Workman; Tim Eisen
Journal: Invest New Drugs Date: 2010-08-05 Impact factor: 3.850

Review 3. HSP90 and the chaperoning of cancer.

Authors: Luke Whitesell; Susan L Lindquist
Journal: Nat Rev Cancer Date: 2005-10 Impact factor: 60.716

4. Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma.

Authors: Tiffany Khong; Andrew Spencer
Journal: Mol Cancer Ther Date: 2011-08-22 Impact factor: 6.261

Review 5. Targeting the dynamic HSP90 complex in cancer.

Authors: Jane Trepel; Mehdi Mollapour; Giuseppe Giaccone; Len Neckers
Journal: Nat Rev Cancer Date: 2010-08 Impact factor: 60.716

6. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts.

Authors: Julie L Eiseman; Jing Lan; Theodore F Lagattuta; Deborah R Hamburger; Erin Joseph; Joseph M Covey; Merrill J Egorin
Journal: Cancer Chemother Pharmacol Date: 2004-08-27 Impact factor: 3.333

7. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.

Authors: Adeela Kamal; Lia Thao; John Sensintaffar; Lin Zhang; Marcus F Boehm; Lawrence C Fritz; Francis J Burrows
Journal: Nature Date: 2003-09-25 Impact factor: 49.962

8. Effect of HSP90 inhibitor in pheochromocytoma PC12 cells: an experimental investigation.

Authors: Yunze Xu; Chongyu Zhang; Dongning Chen; Juping Zhao; Zhoujun Shen; Yuxuan Wu; Yu Zhu
Journal: Tumour Biol Date: 2013-07-20

9. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.

Authors: Sven A Lang; Dagmar Klein; Christian Moser; Andreas Gaumann; Gabriel Glockzin; Marc H Dahlke; Wolfgang Dietmaier; Ulrich Bolder; Hans J Schlitt; Edward K Geissler; Oliver Stoeltzing
Journal: Mol Cancer Ther Date: 2007-03 Impact factor: 6.261